Hwee Teoh

ORCID: 0000-0003-1036-4767
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Metabolism, Diabetes, and Cancer
  • Pancreatic function and diabetes
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Cardiac Valve Diseases and Treatments
  • Lipoproteins and Cardiovascular Health
  • Cardiovascular Disease and Adiposity
  • Angiogenesis and VEGF in Cancer
  • Estrogen and related hormone effects
  • Diabetes Management and Research
  • Nitric Oxide and Endothelin Effects
  • Aortic Disease and Treatment Approaches
  • Autophagy in Disease and Therapy
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Adipose Tissue and Metabolism
  • Aortic aneurysm repair treatments
  • Apelin-related biomedical research
  • Cardiac and Coronary Surgery Techniques
  • Cardiac Structural Anomalies and Repair
  • Menopause: Health Impacts and Treatments
  • Cardiac, Anesthesia and Surgical Outcomes
  • Coronary Interventions and Diagnostics
  • Lipid metabolism and disorders

St. Michael's Hospital
2016-2025

Unity Health Toronto
2019-2025

St Michaels Hospital
2010-2024

22q11 Ireland
2024

St Michael’s Hospital
2024

University of Toronto
2012-2023

Toronto Public Health
2011-2023

St Michael's Hospital
2017-2023

St Michael's Hospital
2021

St Joseph's Health Centre
2019

SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease left ventricular (LV) mass people with and coronary artery disease.Between November 2016 April 2018, we recruited 97 individuals ≥40 ≤80 years old glycated hemoglobin 6.5% 10.0%, known disease, estimated glomerular filtration rate ≥60mL/min/1.73m2. The participants...

10.1161/circulationaha.119.042375 article EN Circulation 2019-08-22

SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular mortality in individuals with type 2 diabetes, although the mechanism(s) of this benefit remain poorly understood. Because changes cardiac bioenergetics play a critical role pathophysiology failure, authors evaluated energy production substrate use diabetic mice treated SGTL2 inhibitor, empagliflozin. Empagliflozin treatment db/db prevented development failure. Glycolysis, oxidation glucose, fatty acids...

10.1016/j.jacbts.2018.07.006 article EN cc-by-nc-nd JACC Basic to Translational Science 2018-08-26

The endothelium plays a central role in the maintenance of vascular homeostasis. One main effectors endothelial dysfunction is ANG II, and pharmacological approaches to limit II bioactivity remain cornerstone cardiovascular therapeutics. Angiotensin converting enzyme-2 (ACE2) has been identified as critical negative modulator bioactivity, counterbalancing effects ACE determining net tissue levels; however, ACE2 vasculature remains unknown. In present study, we hypothesized that novel target...

10.1152/ajpheart.00331.2008 article EN AJP Heart and Circulatory Physiology 2008-07-26

Background— Adropin is a recently identified protein that has been implicated in the maintenance of energy homeostasis and insulin resistance. Because vascular function sensitivity are closely related, we hypothesized adropin may also exert direct effects on endothelium. Methods Results— In vitro cell culture models were partnered with an vivo murine injury model to determine potential adropin. was expressed human umbilical vein coronary artery endothelial cells (ECs). Adropin-treated...

10.1161/circulationaha.109.931782 article EN Circulation 2010-09-13

MicroRNA are essential posttranscriptional modulators of gene expression implicated in various chronic diseases. Because microRNA-145 is highly expressed vascular smooth muscle cells (VSMC) and regulates VSMC fate plasticity, we hypothesized that it may be a novel regulator atherosclerosis plaque stability.Apolipoprotein E knockout mice (ApoE(-/-)) were treated with either lentivirus under the control cell (SMC)-specific promoter SM22α or before commencing Western diet for 12 weeks. The...

10.1161/circulationaha.111.084186 article EN Circulation 2012-09-10

Altered macrophage kinetics is a pivotal mechanism of visceral obesity-induced inflammation and cardiometabolic risk. Because monocytes can differentiate into either proatherogenic M1 macrophages or anti-inflammatory M2 macrophages, approaches that limit while promoting differentiation represent unique therapeutic strategy. We hypothesized adiponectin may prime human toward the phenotype. Adiponectin promoted alternative activation as opposed to classically activated Adiponectin-treated...

10.1152/ajpheart.00115.2010 article EN AJP Heart and Circulatory Physiology 2010-07-12

The tumour suppressor BRCA1 is mutated in familial breast and ovarian cancer but its role protecting other tissues from DNA damage has not been explored. Here we show a new for as gatekeeper of cardiac function survival. In mice, loss cardiomyocytes results adverse remodelling, poor ventricular higher mortality response to ischaemic or genotoxic stress. Mechanistically, cardiomyocyte impaired double-strand break repair activated p53-mediated pro-apoptotic signalling culminating increased...

10.1038/ncomms1601 article EN cc-by-nc-sa Nature Communications 2011-12-20

OBJECTIVE To evaluate the efficacy and safety of inclisiran by diabetes status. RESEARCH DESIGN AND METHODS ORION-1 (ClinicalTrials.gov, NCT02597127) randomized 501 subjects with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents high LDL cholesterol (LDL-C), despite maximally tolerated LDL-C–lowering therapies, to one two doses placebo inclisiran. Levels lipids proprotein convertase subtilisin/kexin type 9 (PCSK9) at baseline day 180 were compared. RESULTS Inclisiran...

10.2337/dc18-1491 article EN Diabetes Care 2018-11-28

Improving endothelial nitric oxide synthase (eNOS) bioactivity and function is important to limit native, vein graft, transplant atherosclerosis. Visfatin, a NAD biosynthetic enzyme, regulates the activity of cellular survival factor, Sirt1. We hypothesized that visfatin may improve eNOS expression, function, postnatal angiogenesis. In human umbilical (HUVEC) coronary artery cells, we evaluated effects recombinant on protein transcript expression mRNA stability, in presence absence RNA...

10.1152/ajpendo.90780.2008 article EN AJP Endocrinology and Metabolism 2009-04-08

Neointimal hyperplasia secondary to vascular smooth muscle cell (VSMC) activation limits the long-term patency of saphenous vein grafts (SVGs). We compared markers injury and VSMC in SVGs harvested using pedicled 'no-touch' (NT) vs conventional (CON) technique. Patients undergoing coronary artery bypass surgery were enrolled PATENT SVG trial (clinicaltrials.gov NCT01488084). randomly allocated have with NT technique from one leg CON method other. segments underwent morphometry, histological...

10.1093/ejcts/ezt560 article EN European Journal of Cardio-Thoracic Surgery 2013-12-09
Coming Soon ...